Peter Neils Le Souëf

Peter Neils Le Souëf

Auto-generated profile, based on publicly available information

Peter Neils Le Souëf

School of Medicine, University of Western Australia

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2008 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
PBP. L. P. Brand
P. L. P. Brand
EBEugenio Baraldi
Eugenio Baraldi
HBHans Bisgaard
Hans Bisgaard
ABA. L. Boner
A. L. Boner
CRCarlos E. Rodriguez-Martinez
Carlos E. Rodriguez-Martinez
ABA. Bush
A. Bush
There is poor agreement on definitions of different phenotypes of preschool wheezing disorders. The present Task Force proposes to use the terms episodic (viral) wheeze to describe children who wheeze intermittently and are well between episodes, and multiple-trigger wheeze for children who wheeze both during and outside discrete episodes. Investigations are only needed when in doubt about the diagnosis.Based on the limited evidence available, inhaled short-acting β2-agonists by metered-dose inhaler/spacer combination are recommended for symptomatic relief. Educating parents regarding causative factors and treatment is useful. Exposure to tobacco smoke should be avoided; allergen avoidance may be considered when sensitisation has been established. Maintenance treatment with inhaled corticosteroids is recommended for multiple-trigger wheeze; benefits are often small. Montelukast is recommended for the treatment of episodic (viral) wheeze and can be started when symptoms of a viral cold develop.Given the large overlap in phenotypes, and the fact that patients can move from one phenotype to another, inhaled corticosteroids and montelukast may be considered on a trial basis in almost any preschool child with recurrent wheeze, but should be discontinued if there is no clear clinical benefit.Large well-designed randomised controlled trials with clear descriptions of patients are needed to improve the present recommendations on the treatment of these common syndromes.

1 September 1996 in Nature
Verified
Journal Article
Closed access
SDSusan E. Daniels
Susan E. Daniels
SBSumit Bhattacharrya
Sumit Bhattacharrya
AJAlan James
Alan James
NLNicholas I. Leaves
Nicholas I. Leaves
AYAlan Young
Alan Young
WCWilliam O. C. M. Cookson
William O. C. M. Cookson

1 October 1996 in The Lancet
Verified
Journal Article
Closed access
SSSm Stick
Sm Stick
PBPr Burton
Pr Burton
LGL Gurrin
L Gurrin
PSPd Sly
Pd Sly
PLPN LeSouëf
PN LeSouëf

1 September 2011 in The Lancet
Verified
Journal Article
Closed access
MFManuel Ar Ferreira
Manuel Ar Ferreira
MMMelanie C Matheson
Melanie C Matheson
DDDavid L Duffy
David L Duffy
GMGuy Marks
Guy Marks
JHJennie Hui
Jennie Hui
PTPhilip J Thompson
Philip J Thompson

25 April 1991 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SYSally Young
Sally Young
PSPeter N. Le Souëf
Peter N. Le Souëf
GGGary C. Geelhoed
Gary C. Geelhoed
SSStephen M. Stick
Stephen M. Stick
KTKeven J. Turner
Keven J. Turner
LLLouis I. Landau
Louis I. Landau
Airway responsiveness to inhaled nonspecific bronchoconstrictive agents has been demonstrated in normal, healthy infants. However, it is unknown whether airway responsiveness is present from birth or if it develops as a result of subsequent insults to the respiratory tract. To investigate this question, we assessed airway responsiveness in 63 normal infants at a mean age of 4 1/2 weeks.

15 June 2012 in Allergy
Verified
Journal Article
Open access
PDF file
NPNikolaos Papadopoulos
Nikolaos Papadopoulos
HAH. Arakawa
H. Arakawa
KCK.‐H. Carlsen
K.‐H. Carlsen
ACA. Custovic
A. Custovic
JGJ. Gern
J. Gern
RZR. S. Zeiger
R. S. Zeiger
Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re‐evaluate and fine‐tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype‐specific treatment choices; however, this goal has not yet been achieved.